A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria.
We tested the efficacy and safety of chlorproguanil/dapsone co-administered with artesunate (CD+A) for the treatment of uncomplicated Plasmodium falciparum malaria in children compared with amodiaquine+sulfadoxine/pyrimethamine (AQ+SP) at two different sites in Rwanda. The trial was open label and 8...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2008
|
| _version_ | 1826279516984573952 |
|---|---|
| author | Fanello, C Karema, C Ngamije, D Uwimana, A Ndahindwa, V Van Overmeir, C Van Doren, W Curtis, J D'Alessandro, U |
| author_facet | Fanello, C Karema, C Ngamije, D Uwimana, A Ndahindwa, V Van Overmeir, C Van Doren, W Curtis, J D'Alessandro, U |
| author_sort | Fanello, C |
| collection | OXFORD |
| description | We tested the efficacy and safety of chlorproguanil/dapsone co-administered with artesunate (CD+A) for the treatment of uncomplicated Plasmodium falciparum malaria in children compared with amodiaquine+sulfadoxine/pyrimethamine (AQ+SP) at two different sites in Rwanda. The trial was open label and 800 patients were randomly assigned to AQ+SP (n=400) or CD+A (n=400). Patients were hospitalised for 3 days and then followed-up weekly until Day 28 after treatment. Clinical and parasitological outcomes were recorded. Results showed that neither treatment was adequately efficacious. At one site, the adequate clinical and parasitological response (ACPR), PCR-adjusted, was 73.3% in the CD+A arm and 87.8% in the AQ+SP arm (P<0.001), and at the second site the ACPR, PCR-adjusted, was 70.5% in the CD+A arm and 38.1% in the AQ+SP arm (P<0.001). The combination CD+A is considered an alternative to, or replacement for, SP in Africa because CD has been shown to be effective in patients for whom SP treatment has failed and, with its short half-life, it is expected to exert less selection pressure for resistant parasites than SP. However, the results of this trial indicate that in an area of high SP resistance, CD+A may not be the best choice. |
| first_indexed | 2024-03-06T23:59:54Z |
| format | Journal article |
| id | oxford-uuid:7592c6bc-b79f-4be3-a076-55d718ac576d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:59:54Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:7592c6bc-b79f-4be3-a076-55d718ac576d2022-03-26T20:10:08ZA randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7592c6bc-b79f-4be3-a076-55d718ac576dEnglishSymplectic Elements at Oxford2008Fanello, CKarema, CNgamije, DUwimana, ANdahindwa, VVan Overmeir, CVan Doren, WCurtis, JD'Alessandro, UWe tested the efficacy and safety of chlorproguanil/dapsone co-administered with artesunate (CD+A) for the treatment of uncomplicated Plasmodium falciparum malaria in children compared with amodiaquine+sulfadoxine/pyrimethamine (AQ+SP) at two different sites in Rwanda. The trial was open label and 800 patients were randomly assigned to AQ+SP (n=400) or CD+A (n=400). Patients were hospitalised for 3 days and then followed-up weekly until Day 28 after treatment. Clinical and parasitological outcomes were recorded. Results showed that neither treatment was adequately efficacious. At one site, the adequate clinical and parasitological response (ACPR), PCR-adjusted, was 73.3% in the CD+A arm and 87.8% in the AQ+SP arm (P<0.001), and at the second site the ACPR, PCR-adjusted, was 70.5% in the CD+A arm and 38.1% in the AQ+SP arm (P<0.001). The combination CD+A is considered an alternative to, or replacement for, SP in Africa because CD has been shown to be effective in patients for whom SP treatment has failed and, with its short half-life, it is expected to exert less selection pressure for resistant parasites than SP. However, the results of this trial indicate that in an area of high SP resistance, CD+A may not be the best choice. |
| spellingShingle | Fanello, C Karema, C Ngamije, D Uwimana, A Ndahindwa, V Van Overmeir, C Van Doren, W Curtis, J D'Alessandro, U A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. |
| title | A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. |
| title_full | A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. |
| title_fullStr | A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. |
| title_full_unstemmed | A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. |
| title_short | A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. |
| title_sort | randomised trial to assess the efficacy and safety of chlorproguanil dapsone artesunate for the treatment of uncomplicated plasmodium falciparum malaria |
| work_keys_str_mv | AT fanelloc arandomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT karemac arandomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT ngamijed arandomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT uwimanaa arandomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT ndahindwav arandomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT vanovermeirc arandomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT vandorenw arandomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT curtisj arandomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT dalessandrou arandomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT fanelloc randomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT karemac randomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT ngamijed randomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT uwimanaa randomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT ndahindwav randomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT vanovermeirc randomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT vandorenw randomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT curtisj randomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria AT dalessandrou randomisedtrialtoassesstheefficacyandsafetyofchlorproguanildapsoneartesunateforthetreatmentofuncomplicatedplasmodiumfalciparummalaria |